• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尿道透明细胞腺癌的组织学和免疫组织化学:组织发生和诊断问题。

Histology and immunohistochemistry of clear cell adenocarcinoma of the urethra: histogenesis and diagnostic problems.

机构信息

Department of Pathology, NBW85, University of Maryland Medical Center, 22 S Greene Street, Baltimore, MD 21201, USA.

出版信息

Virchows Arch. 2013 Feb;462(2):193-201. doi: 10.1007/s00428-012-1363-3. Epub 2013 Jan 11.

DOI:10.1007/s00428-012-1363-3
PMID:23307189
Abstract

Clear cell adenocarcinoma (CCAC) of the urethra is a rare neoplasm, morphologically identical to its homologue arising in the female genital tract. The histogenesis of this neoplasm is uncertain. We present clinical, histopathologic, and immunohistochemical findings of four CCAC of the urethra and discuss the histogenesis and difficulties in diagnosis and differential diagnosis. CCAC of the urethra occurred in females (4/4). Two neoplasms were identified in urethral diverticulum; one of the two cases, in close proximity to a nephrogenic adenoma. CCAC exhibited tubulocystic, papillary, and diffuse/solid growth patterns. The neoplastic cells were cuboidal or columnar with eosinophilic or clear cytoplasm, and nuclear pleomorphism of at least moderate degree. Hobnail features and tumor necrosis were also observed. CCAC expressed p53 (4/4), AMACR (3/4), vimentin (3/4), PAX8 (2/4), CK7 (2/4), cytokeratin 34betaE12 (2/4), RCC (1/4), and CK20 (1/4) and were negative for PSA, WT1, ER, CA 125, uroplakin III, p16, and p63. The immunohistochemical profile supports a possible renal tubular cell differentiation/mesonephric origin for some urethral CCAC. Nephrogenic adenoma and metastatic clear cell carcinoma are the most important differential diagnostic considerations. Multicenter studies on more cases may improve our understanding of this malignancy.

摘要

尿道透明细胞腺癌(CCAC)是一种罕见的肿瘤,其形态与女性生殖道同源肿瘤完全相同。该肿瘤的组织发生尚不确定。我们介绍了 4 例尿道 CCAC 的临床、组织病理学和免疫组织化学表现,并讨论了其组织发生、诊断和鉴别诊断的难点。尿道 CCAC 发生于女性(4/4)。2 例肿瘤位于尿道憩室中,其中 1 例与肾源性腺瘤相邻。CCAC 表现为管状囊状、乳头状和弥漫/实性生长方式。肿瘤细胞为立方或柱状,胞浆嗜酸性或透明,核异型性至少为中度。也观察到鞋钉样特征和肿瘤坏死。CCAC 表达 p53(4/4)、AMACR(3/4)、波形蛋白(3/4)、PAX8(2/4)、CK7(2/4)、细胞角蛋白 34βE12(2/4)、RCC(1/4)和 CK20(1/4),并对 PSA、WT1、ER、CA125、尿路上皮 III 型、p16 和 p63 均为阴性。免疫组织化学特征支持部分尿道 CCAC 可能来源于肾小管细胞分化/中肾。肾源性腺瘤和转移性透明细胞癌是最重要的鉴别诊断考虑因素。对更多病例的多中心研究可能会提高我们对这种恶性肿瘤的认识。

相似文献

1
Histology and immunohistochemistry of clear cell adenocarcinoma of the urethra: histogenesis and diagnostic problems.尿道透明细胞腺癌的组织学和免疫组织化学:组织发生和诊断问题。
Virchows Arch. 2013 Feb;462(2):193-201. doi: 10.1007/s00428-012-1363-3. Epub 2013 Jan 11.
2
Clear cell adenocarcinoma of urinary bladder and urethra: another urinary tract lesion immunoreactive for P504S.膀胱和尿道透明细胞腺癌:另一种对P504S呈免疫反应性的泌尿道病变。
Arch Pathol Lab Med. 2008 Sep;132(9):1417-22. doi: 10.5858/2008-132-1417-CCAOUB.
3
Clear cell adenocarcinoma and nephrogenic adenoma of the urethra and urinary bladder: a histopathologic and immunohistochemical comparison.尿道及膀胱的透明细胞腺癌和肾源性腺瘤:组织病理学与免疫组化比较
Hum Pathol. 1998 Dec;29(12):1451-6. doi: 10.1016/s0046-8177(98)90015-6.
4
Clear cell adenocarcinoma of the bladder and urethra: cases diffusely mimicking nephrogenic adenoma.膀胱和尿道透明细胞腺癌:弥漫性酷似肾源性腺瘤的病例。
Hum Pathol. 2010 Apr;41(4):594-601. doi: 10.1016/j.humpath.2009.10.011. Epub 2010 Jan 8.
5
Hepatocyte nuclear factor-1β expression in clear cell adenocarcinomas of the bladder and urethra: diagnostic utility and implications for histogenesis.肝细胞核因子-1β在膀胱和尿道透明细胞腺癌中的表达:诊断效用及其对组织发生的意义。
Hum Pathol. 2011 Nov;42(11):1613-9. doi: 10.1016/j.humpath.2011.01.007. Epub 2011 Apr 14.
6
Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis?PAX8在下尿路肾源性腺瘤和透明细胞腺癌中的表达:相关组织发生的证据?
Am J Surg Pathol. 2008 Sep;32(9):1380-7. doi: 10.1097/PAS.0b013e31816b1020.
7
Clear cell carcinoma of the urinary bladder: a report and comparison of four tumors of mullerian origin and nine of probable urothelial origin with discussion of histogenesis and diagnostic problems.膀胱透明细胞癌:4例苗勒管起源肿瘤及9例可能为尿路上皮起源肿瘤的报告与比较,并讨论组织发生及诊断问题
Am J Surg Pathol. 2002 Feb;26(2):190-7. doi: 10.1097/00000478-200202000-00005.
8
Clear cell adenocarcinoma of the urethra: a clinicopathologic analysis of 19 cases.尿道透明细胞腺癌:19例临床病理分析
Mod Pathol. 1996 May;9(5):513-20.
9
Tubular adenomatous metaplasia (nephrogenic adenoma) of the female urethra.女性尿道的管状腺瘤样化生(肾源性腺瘤)。
Int J Gynecol Pathol. 1989;8(4):374-80. doi: 10.1097/00004347-198912000-00009.
10
Napsin-A and AMACR are Superior to HNF-1β in Distinguishing Between Mesonephric Carcinomas and Clear Cell Carcinomas of the Gynecologic Tract. napsin-A 和 AMACR 在鉴别妇科管腔型癌和透明细胞癌中的 Mesonephric 癌优于 HNF-1β。
Appl Immunohistochem Mol Morphol. 2020 Sep;28(8):593-601. doi: 10.1097/PAI.0000000000000801.

引用本文的文献

1
Comprehensive Molecular, Pathological, and Clinical Characterization of Clear Cell Adenocarcinoma of the Urinary Tract.泌尿道透明细胞腺癌的综合分子、病理及临床特征
Mod Pathol. 2025 Jun 18;38(10):100821. doi: 10.1016/j.modpat.2025.100821.
2
[Rare tumors and tumor types of the urinary system in the 5th edition of the WHO classification 2022].[2022年世界卫生组织分类第5版中的泌尿系统罕见肿瘤及肿瘤类型]
Pathologie (Heidelb). 2024 Nov;45(6):381-388. doi: 10.1007/s00292-024-01329-2. Epub 2024 Apr 19.
3
Clear Cell Adenocarcinoma of Urethra: Clinical and Pathologic Implications and Characterization of Molecular Aberrations.

本文引用的文献

1
Adenocarcinoma of the female urethra: Clear-cell variant.女性尿道腺癌:透明细胞变异型。
Radiol Case Rep. 2015 Nov 6;6(3):490. doi: 10.2484/rcr.v6i3.490. eCollection 2011.
2
Hepatocyte nuclear factor-1β expression in clear cell adenocarcinomas of the bladder and urethra: diagnostic utility and implications for histogenesis.肝细胞核因子-1β在膀胱和尿道透明细胞腺癌中的表达:诊断效用及其对组织发生的意义。
Hum Pathol. 2011 Nov;42(11):1613-9. doi: 10.1016/j.humpath.2011.01.007. Epub 2011 Apr 14.
3
Chromosomal abnormalities in renal cell carcinoma variants detected by Urovysion fluorescence in situ hybridization on paraffin-embedded tissue.
尿道透明细胞腺癌:临床病理意义及分子异常特征。
Cancer Res Treat. 2024 Jan;56(1):280-293. doi: 10.4143/crt.2023.577. Epub 2023 Sep 11.
4
Personalized chemotherapy in clear cell adenocarcinoma of the urethra: A case report.尿道透明细胞腺癌的个体化化疗:病例报告
World J Clin Oncol. 2020 Apr 24;11(4):243-249. doi: 10.5306/wjco.v11.i4.243.
5
Dataset for the reporting of carcinoma of the bladder-cystectomy, cystoprostatectomy and diverticulectomy specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR).膀胱癌-膀胱切除术、膀胱前列腺切除术和憩室切除术标本报告数据集:国际癌症报告合作组织(ICCR)的建议。
Virchows Arch. 2020 Apr;476(4):521-534. doi: 10.1007/s00428-019-02727-1. Epub 2020 Jan 8.
6
Unusual Features of Clear Cell Adenocarcinoma of the Female Urethra: A Case Report and Literature Review.女性尿道透明细胞腺癌的不寻常特征:一例报告及文献综述
J Clin Med Res. 2018 Aug;10(8):665-667. doi: 10.14740/jocmr3500w. Epub 2018 Jun 27.
7
Primary urethral clear-cell adenocarcinoma: comprehensive analysis by surgical pathology, cytopathology, and next-generation sequencing.原发性尿道透明细胞腺癌:通过外科病理学、细胞病理学和下一代测序进行的综合分析
Am J Pathol. 2014 Mar;184(3):584-91. doi: 10.1016/j.ajpath.2013.11.023. Epub 2014 Jan 3.
8
Utility of α-methylacyl-coenzyme-A racemase (p504s) immunohistochemistry in distinguishing endometrial clear cell carcinomas from serous and endometrioid carcinomas.α-甲基酰基辅酶 A 消旋酶(p504s)免疫组化在鉴别子宫内膜透明细胞癌与浆液性和子宫内膜样癌中的作用。
Hum Pathol. 2013 Dec;44(12):2814-21. doi: 10.1016/j.humpath.2013.07.033. Epub 2013 Oct 10.
应用 Urovysion 荧光原位杂交技术检测石蜡包埋组织中肾细胞癌变异型的染色体异常。
Ann Diagn Pathol. 2011 Feb;15(1):37-45. doi: 10.1016/j.anndiagpath.2010.07.011.
4
Clear cell adenocarcinoma of the bladder and urethra: cases diffusely mimicking nephrogenic adenoma.膀胱和尿道透明细胞腺癌:弥漫性酷似肾源性腺瘤的病例。
Hum Pathol. 2010 Apr;41(4):594-601. doi: 10.1016/j.humpath.2009.10.011. Epub 2010 Jan 8.
5
Clear cell adenocarcinoma of the urinary bladder: a short review.膀胱透明细胞腺癌:简要综述
Arch Pathol Lab Med. 2009 Jun;133(6):987-91. doi: 10.5858/133.6.987.
6
Clear cell adenocarcinoma of the bladder and urethra.膀胱及尿道透明细胞腺癌
J Urol. 2008 Dec;180(6):2656. doi: 10.1016/j.juro.2008.09.064. Epub 2008 Oct 31.
7
Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis?PAX8在下尿路肾源性腺瘤和透明细胞腺癌中的表达:相关组织发生的证据?
Am J Surg Pathol. 2008 Sep;32(9):1380-7. doi: 10.1097/PAS.0b013e31816b1020.
8
Histogenesis of clear cell adenocarcinoma in the urinary tract: evidence of urothelial origin.泌尿道透明细胞腺癌的组织发生:尿路上皮起源的证据。
Clin Cancer Res. 2008 Apr 1;14(7):1947-55. doi: 10.1158/1078-0432.CCR-07-4147.
9
Incidence of primary urethral carcinoma in the United States.美国原发性尿道癌的发病率。
Urology. 2006 Dec;68(6):1164-8. doi: 10.1016/j.urology.2006.08.1057. Epub 2006 Dec 4.
10
Mesonephroid adenocarcinoma arising from mesonephroid metaplasia of the urinary bladder.起源于膀胱中肾样化生的中肾样腺癌。
Urology. 2006 Apr;67(4):846.e7-8. doi: 10.1016/j.urology.2005.10.035. Epub 2006 Mar 29.